Resistance to therapy is a frequently observed phenomenon in the treatment of cancer, and
as with other cancer therapeutics, therapies based on oncolytic viruses also face the …

Vesicular stomatitis virus (VSV) represents a significant advancement in therapeutic
medicine, offering unique molecular and cellular characteristics that make it exceptionally …

The emergence of cellular resistances to oncolytic viruses is an underexplored process that
could compromise the efficacy of cancer virotherapy. Here, we isolated and characterized …

Abstract Background Oncolytic viruses (OVs) are increasingly recognized as promising tools
for cancer therapy, as they selectively infect and destroy tumor cells while leaving healthy …

Hepatocellular carcinoma (HCC), one of the most common lethal diseases in the world, has
a 5-year survival rate of only 7%. Hepatocellular carcinoma has no symptoms in the early …

Background The immunosuppressive microenvironment in pancreatic ductal
adenocarcinoma is a major factor that limits the benefits of immunotherapy, especially …

Vesicular Stomatitis Virus (VSV) has emerged as a promising candidate for various clinical
applications, including vaccine development, virus pseudotyping, and gene delivery. Its …

Simple Summary Immune checkpoint inhibitors (ICIs) are the most recent breakthrough in
cancer treatments. Several drugs have been approved by the FDA including anti-PD-1 …

Plant viruses trigger numerous responses in their insect vectors. Using iTRAQ-based
quantitative proteomics analysis, early responses of the insect vector, the small brown …

Oncolytic viruses (OVs) represent a targeted anti-cancer therapy approach due to their
ability not only to selectively infect and destroy malignant cells but also to induce an immune …